Today: 7 February 2026
Subscribe
Browse Category

NYSE:MMC News 16 October 2025 - 19 October 2025

Marsh CEO Slams Rivals’ “Unlawful” Hiring Blitz as Shares Slide

Marsh CEO Slams Rivals’ “Unlawful” Hiring Blitz as Shares Slide

Marsh & McLennan CEO John Doyle publicly accused rival brokers of “unlawful and unethical” talent raids during Marsh’s Oct. 16 earnings call Insuranceinsider Theinsurer. Doyle said competitors’ tactics were a “deliberate strategy” to flout non-compete covenants Insuranceinsider. The comments came amid a surge of legal battles – Marsh has sued peers like Alliant and Howden for allegedly poaching its teams and clients Insurancejournal Insurancebusinessmag. In Q3, Marsh reported $6.4 billion revenue (up 11% YoY) and $911 million adjusted profit Reuters, but its stock still plunged ~8% on the day Reuters, trading around $190 (mid-Oct. 2025) Stockanalysis. Analysts remain cautiously bullish: the consensus
19 October 2025
··
Marsh & McLennan’s Q3 Profit Jumps 11% Amid Rebrand to “Marsh” – What’s Next for MMC Stock?

Marsh & McLennan’s Q3 Profit Jumps 11% Amid Rebrand to “Marsh” – What’s Next for MMC Stock?

Q3 2025 Earnings: Solid Growth and an 11% Profit Jump Marsh & McLennan delivered a strong third quarter, topping expectations on both the top and bottom lines. Revenue reached $6.4 billion, up 11% from a year ago (4% on an underlying, constant-currency basis) stocktitan.net stocktitan.net. This was driven by double-digit growth in its core insurance broking unit and steady gains in consulting. The Risk & Insurance Services division (which includes its Marsh insurance brokerage and Guy Carpenter reinsurance arm) saw revenue surge +13% year-over-year to $3.9 billion stocktitan.net, boosted by firm insurance pricing earlier in the year and a rebound in client
16 October 2025
····

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Go toTop